EUCTR2014-004953-14-Outside-EU/EEA进行中（未招募）不适用
A Phase 3, Randomized, Active-Controlled Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in China
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer, Inc.
- 入组人数
- 1,674
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Evidence of a personally signed and dated informed consent document indicating that the subject’s parent/legal guardian has been informed of all pertinent aspects of the study.
- •2. Subject’s caregiver willing and able to comply with scheduled visits, laboratory tests, and other study procedures. The subject’s caregiver must be able to be reached by telephone for the duration of the study.
- •3. Male or female subject aged 42 to 77 days (approximately 2 months) at the time of enrollment.
- •4. Healthy infant as determined by medical history, physical examination, and judgment of the investigator.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1674
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous vaccination with licensed or investigational pneumococcal vaccine.
- •2. A previous anaphylactic reaction to any vaccine or vaccine-related component.
- •3. Contraindication to vaccination with pneumococcal vaccines.
- •4. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
- •5. Known or suspected immune deficiency or suppression.
- •6. History of culture-proven invasive disease caused by Streptococcus pneumoniae.
- •7. Major known congenital malformation or serious chronic disorder.
- •8. Significant neurological disorder or history of seizure including febrile seizure, or significant stable or evolving disorder such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorder. Resolving syndromes due to birth trauma such as perception before Brachial plexus birth palsy (Erb palsy) not included.
- •9. Receipt of blood products or gamma globulin. Hepatitis B immunoglobulin might be given.
- •10. Participation in another investigational trial within 28 days before the current study begins and during study participation. Participation in purely observational studies acceptable
- •11. Subjects whose parents or legal guardian are investigational site staff members or subjects whose parents or legal guardian are Pfizer employees directly involved in the conduct of the trial.
- •12. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that increased the risk associated with study participation or investigational product administration or interfered with the interpretation of study results and, in the judgment of the investigator, made the subject inappropriate for entry into this study
- •13. Known or suspected allergy to 13vPnC, 7vPnC, or other compounds related to these classes of medication.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults with Very Early RA - NDRheumatoid ArthritisMedDRA version: 9.1Level: LLTClassification code 10039073EUCTR2010-018674-20-ITBristol Myers Squibb International Corporation470
进行中（未招募）
不适用
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination WithMethotrexate in Adults With Very Early Rheumatoid Arthritis (RA)MedDRA version: 15.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-018674-20-SEBristol Myers Squibb International Corporation470
进行中（未招募）
不适用
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination WithMethotrexate in Adults With Very Early Rheumatoid Arthritis (RA)MedDRA version: 16.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-018674-20-FIBristol Myers Squibb International Corporation470
进行中（未招募）
1 期
A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety ofAbatacept SC in Combination with Methotrexate in Inducing Clinical RemissionCompared to Methotrexate Monotherapy in Adults with Very Early RA.MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2010-018674-20-FRBristol Myers Squibb International Corporation511
进行中（未招募）
不适用
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)MedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-018674-20-DEBristol Myers Squibb International Corporation470